A Multicenter Open-Label Phase 1a/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
Latest Information Update: 16 Jan 2025
At a glance
- Drugs BGBR 046 (Primary) ; Tislelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors BeiGene
- 29 Jul 2024 Status changed from not yet recruiting to recruiting.
- 19 Jul 2024 New trial record